Dishman Carbogen Amcis Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹716Cr
- +9.3% YoY
- +5% QoQ
- Net profit
- ₹43Cr
- Turned profitable YoY
- +760% QoQ
- Margin
- 21%
- +11 pp YoY
- 0 pp QoQ
Guidance rank: #82 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Dishman Carbogen Amcis Ltd Q4 FY25 key numbers
- Revenue
- Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years.
As stated in Dishman Carbogen Amcis Ltd's Q4 FY25 earnings call transcript · published 14 Jun 2026. Reported figures, not investment advice.
The short version
The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin.
From Dishman Carbogen Amcis Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. (Page 10)
- India CRAMS business is expected to grow by 15% to 20% in FY ‘26. (Page 9)
- The Quats and Generics business is expected to grow between 5% to 10%. (Page 9)
- Peak revenue from India assets could reach around INR 800 crores within 2 to 3 years. (Pages 13-14)
- Bavla site's quarterly revenue is anticipated to reach around INR 100 crores in the later part of FY ‘26. (Page 15)
- EBITDA targeted at INR 550 crores to INR 570 crores in FY ‘26, with potential for higher margins than 20%. (Page 22)
2 more points from Dishman Carbogen Amcis Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million).
- Maintenance CAPEX is around INR 170-180 crores; the remainder is growth CAPEX including digital transformation initiatives.
- Large CAPEX for the French entity is mostly behind; future CAPEX will focus on expansion based on confirmed business cases.
- Co-investment of EUR 25 million by a Japanese customer for a specific project; infrastructure investment is a core investment paid by the client.
- Additional investments are planned in product expansion projects in Europe and India.
- Focus on CAPEX only when there is committed revenue from customers to ensure returns.
2 more points from Dishman Carbogen Amcis Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The discussion indicates a positive outlook on upcoming projects, with a focus on early-phase and late-phase (Phase IIb and Phase III) projects.
- The company is investing in market intelligence to identify new opportunities and potentially become a secondary supplier for risk mitigation.
- There is a mention of strong interest and investment in the CRAMS business and API development with expected growth.
2 more points from Dishman Carbogen Amcis Ltd's call on order book
Create a free account to keep reading this call
Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit
Dishman Carbogen Amcis Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 716 | 655 | +9.3% | 682 | +5% |
| Operating profit (EBITDA) | 153 | 63 | +142.9% | 140 | +9.3% |
| Operating margin | 21% | 10% | +11 pp | 21% | 0 pp |
| Profit before tax | 28 | -49 | — | 27 | +3.7% |
| Net profit (PAT) | 43 | -70 | — | 5 | +760% |
| EPS (₹) | 2.75 | -4.46 | — | 0.30 | +816.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹507 Cr, net loss ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dishman Carbogen's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dishman Carbogen Amcis Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dishman Carbogen Amcis Ltd Q4 FY25 results?
The company targets a low double-digit revenue growth, aiming for a CAGR of 12% to 15% over the next 3 to 5 years. EBITDA for FY '26 is expected between INR 550 crores to INR 570 crores, targeting a 20% margin.
What is Dishman Carbogen Amcis Ltd share price analysis?
Dishman Carbogen Amcis Ltd currently shows a neutral. The stock trades at a P/E of 164.8 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dishman Carbogen Amcis Ltd planning capital expenditure?
FY ‘26 CAPEX guidance is approximately INR 250 crores to INR 300 crores (EUR 25-30 million).
Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
